Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

488
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
488
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

498
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
498
Hemodialysis III: Nursing Management01:25

Hemodialysis III: Nursing Management

1.6K
The nursing management of a patient undergoing hemodialysis includes several critical steps, starting with a thorough assessment before the procedure.Before the Hemodialysis ProcedureFirst, record the patient's vital signs—blood pressure, heart rate, respiratory rate, and temperature—to establish a baseline. This baseline is essential for detecting conditions such as hypotension that could impact the patient's response to dialysis. Document the patient's pre-dialysis weight, as this...
1.6K
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

357
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
357
Acute Kidney Injury VI: Nursing Management01:22

Acute Kidney Injury VI: Nursing Management

728
Acute Kidney Injury (AKI) results in an inability to maintain fluid, electrolyte, and acid-base balance. Effective nursing management is critical in improving patient outcomes and includes comprehensive patient assessment and targeted interventions.Comprehensive Patient AssessmentA detailed history collection is essential, focusing on any recent infections, nephrotoxic medication use, or chronic conditions such as hypertension and diabetes that may contribute to AKI. During the physical...
728
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

655
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
655

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A decade of complement inhibition in post-transplant atypical HUS: outcomes with eculizumab and ravulizumab.

Clinical kidney journal·2026
Same author

Monoclonal nephritic factors reveal insights into C3 convertase dynamics and dysregulation.

bioRxiv : the preprint server for biology·2026
Same author

Pegcetacoplan for Adolescents with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative GN: Phase 3 VALIANT Subgroup Analysis.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same author

Complement biomarkers during iptacopan treatment - Authors' reply.

Lancet (London, England)·2026
Same author

Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN. Reply.

The New England journal of medicine·2026
Same author

Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN.

The New England journal of medicine·2025

Related Experiment Video

Updated: Apr 12, 2026

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

20.7K

Managing atypical hemolytic uremic syndrome: chapter 2.

Carla M Nester1

  • 11] Stead Family Department of Pediatrics, University of Iowa, Iowa City, USA [2] Department of Internal Medicine, University of Iowa, Iowa City, USA.

Kidney International
|May 8, 2015
PubMed
Summary

Eculizumab demonstrated sustained efficacy and safety over two years for atypical hemolytic uremic syndrome (aHUS). Extended treatment showed continued hematologic improvement and enhanced kidney function in aHUS patients.

More Related Videos

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

2.0K
Development of Human Renal Tubular Epithelial Cell Primary Cultures in Monolayers and Three-Dimensional Conditions
06:32

Development of Human Renal Tubular Epithelial Cell Primary Cultures in Monolayers and Three-Dimensional Conditions

Published on: June 13, 2025

656

Related Experiment Videos

Last Updated: Apr 12, 2026

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

20.7K
A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

2.0K
Development of Human Renal Tubular Epithelial Cell Primary Cultures in Monolayers and Three-Dimensional Conditions
06:32

Development of Human Renal Tubular Epithelial Cell Primary Cultures in Monolayers and Three-Dimensional Conditions

Published on: June 13, 2025

656

Area of Science:

  • Nephrology
  • Hematology
  • Rare Diseases

Background:

  • Atypical hemolytic uremic syndrome (aHUS) is a rare, life-threatening thrombotic microangiopathy.
  • Eculizumab has shown promise in treating aHUS, but long-term data are crucial.

Purpose of the Study:

  • To present 2-year follow-up data from landmark trials on eculizumab for aHUS.
  • To assess the sustained efficacy and safety of eculizumab in aHUS patients.

Main Methods:

  • Analysis of 2-year follow-up data from clinical trials.
  • Evaluation of hematologic parameters, kidney function, and safety events.

Main Results:

  • Sustained improvements in hematologic parameters were observed.
  • Continued safety profile with extended eculizumab treatment.
  • Additional improvements in kidney function noted with longer treatment duration.

Conclusions:

  • Eculizumab provides sustained benefits for aHUS patients over two years.
  • Extended treatment appears safe and offers further renal protection.
  • Further research is needed to fully define the long-term aHUS treatment landscape.